1. What Is the Psoriasis Biologics Market?
The Psoriasis Biologics Market covers biologic and targeted synthetic therapies managing moderate-to-severe plaque psoriasis including TNF inhibitors, IL-17 inhibitors, IL-23 inhibitors, and IL-12/23 inhibitors. Dermatologists and immunology specialists deploy psoriasis biologics for patients with inadequate response to conventional topical and phototherapy treatments. The market includes established biologics, biosimilars of earlier-generation products, and next-generation selective IL-23 inhibitors achieving high complete skin clearance rates.
2. Psoriasis Biologics Market Size & Forecast
3. Emerging Technologies
- Subcutaneous IL-23 inhibitors with extended maintenance dosing intervals enabling patients to self-administer therapy with minimal treatment burden.
- Personalized psoriasis therapy selection using genomic and biomarker profiling to identify optimal biologic mechanism for individual patients.
- Topical JAK inhibitors and phosphodiesterase inhibitors expanding non-injection options for moderate psoriasis patients.
- AI-powered psoriasis disease severity assessment using dermatology imaging to quantify treatment response and guide therapy adjustments.
Comparable technologies are influencing adjacent market segments in similar ways. Read more in our Inflammatory Bowel Disease Treatment Market.
4. Key Market Opportunity
IL-23 selective inhibitor market leadership represents the largest commercial growth opportunity. Johnson and Johnson guselkumab and AbbVie risankizumab are building dominant positions in biologic-experienced psoriasis patients. Biologic-naive patient market expansion driven by earlier treatment guideline adoption is the largest patient volume growth opportunity. Asian market psoriasis biologic adoption expansion represents the largest geographic growth opportunity.
5. Top Companies in the Psoriasis Biologics Market
The following organisations hold leading positions in the Psoriasis Biologics Market. The full report provides revenue share, SWOT analysis, and competitive benchmarking for each player.
- AbbVie
- Johnson and Johnson
- Novartis
- UCB
- Eli Lilly
- Bristol Myers Squibb
- Leo Pharma
- Almirall
- Boehringer Ingelheim
- Samsung Bioepis
6. Market Segmentation
The Psoriasis Biologics Market is analysed across 5 segmentation dimensions. Revenue data, growth rates, and competitive intensity by sub-segment are available in the full report.
| Segmentation | Sub-Segments |
|---|---|
| By Drug Class | TNF-Alpha InhibitorsIL-17A InhibitorsIL-23 Selective InhibitorsIL-12/23 InhibitorsPDE4 Inhibitors |
| By Psoriasis Type | Plaque PsoriasisPsoriatic ArthritisPustular PsoriasisErythrodermic Psoriasis |
| By Treatment Setting | Dermatology OfficeSpecialty PharmacyHospital Dermatology |
| By Patient Profile | Biologic-NaiveBiologic-ExperiencedTNF-Inadequate Responders |
| By Geography | North AmericaEuropeAsia PacificLatin AmericaMiddle East and Africa |
7. Key Market Trends (2026–2034)
Three major forces are shaping the Psoriasis Biologics Market trajectory over the forecast period:
IL-23 selective inhibitors are achieving market leadership as guselkumab, risankizumab, and tildrakizumab demonstrate superior or comparable skin clearance with more convenient dosing than earlier biologics.Quarterly or twice-yearly maintenance dosing of IL-23 inhibitors versus more frequent dosing of TNF and IL-17 inhibitors creates patient adherence advantages. The IL-23 selective category is creating sustained commercial growth through superior patient and physician preference.
Biologic-naive patient market expansion is growing as dermatologists become more comfortable prescribing biologics earlier in the treatment pathway.Guideline updates supporting biologic initiation in moderate-to-severe psoriasis patients without extensive conventional therapy failure are expanding the addressable biologic-naive patient population. The earlier treatment initiation trend is driving systematic market expansion across the psoriasis biologics category.
Biosimilar competition for adalimumab and etanercept in psoriasis is creating commercial restructuring as biosimilars capture market share at substantially lower prices.Biosimilar manufacturers including Sandoz, Amgen, and Samsung Bioepis are gaining psoriasis market share from originator TNF inhibitors. The biosimilar market share gains are driving commercial pressure on TNF inhibitor revenues while creating net market growth through access expansion.
For related market intelligence, see the Rheumatoid ARthritis Drugs Market.
8. Segmental Analysis
By drug class, the IL-17A inhibitors segment dominated the Psoriasis Biologics Market in 2025, as secukinumab, ixekizumab, and bimekizumab represent the largest psoriasis biologic revenue category driven by superior skin clearance versus TNF inhibitors sustaining dermatologist prescribing preference.
By drug class, the IL-23 selective inhibitors segment is projected to register the highest growth rate through 2034, as quarterly and biannual dosing convenience combined with high sustained clearance rates are driving systematic prescribing conversion from earlier biologic mechanisms.
9. Regional Analysis
Regional demand patterns across the Psoriasis Biologics Market reflect differences in regulation, technological maturity, and capital investment.
Largest Market Share
North America dominated the Psoriasis Biologics Market in 2025, accounting for around 47 percent of global revenue. The United States represents the world's largest psoriasis biologic market driven by high dermatologist biologic prescribing rates and comprehensive specialty pharmacy access. AbbVie, Johnson and Johnson, and UCB generate substantial U.S. psoriasis commercial revenue. Moreover, U.S. dermatology infrastructure supports the broadest biologic prescribing access globally.
Highest CAGR Region
Asia Pacific is projected to register the highest CAGR in the Psoriasis Biologics Market through 2034. The region's expanding dermatology infrastructure combined with growing biologic reimbursement is driving substantial psoriasis biologic adoption. Chinese psoriasis biologic market expansion driven by domestic biologic development and reimbursement inclusion is creating substantial regional demand. Japanese and Korean dermatology prescribing supports sustained regional biologic market growth.
10. Full Report with Exclusive Insights
The complete published market report includes an in-depth analysis of market dynamics, industry trends, competitive landscape, regional outlook, and future growth opportunities. The study provides detailed market sizing and forecasts across key segments and geographies, along with comprehensive insights into drivers, restraints, opportunities, challenges, technological advancements, regulatory landscape, and evolving consumer and industry trends. The report also features company profiles, strategic developments, market share analysis, and actionable recommendations to support informed business decision-making. Additionally, the syndicated report package typically includes forecast datasets, charts and figures, research methodology, and analyst support for strategic interpretation and planning.
Advanced Strategic & Custom Intelligence
In addition to the standard syndicated report package, TrendX Insights can provide the following advanced strategic analyses and customized intelligence solutions for any market:
Standard Report Coverage
- • Competitor Analysis
- • Country Trade Analysis
- • Import & Export Analysis
- • Porter’s Five Forces Analysis
- • SWOT Analysis by Companies
- • TrendX Insights Quadrant Positioning
- • Pricing Analysis
- • Detailed Macro-Economic Indicators Assessment
- • List of Raw Material Suppliers
- • Regulatory Framework Assessment
- • Supply Chain Resilience Mapping
- • Value Chain Analysis
- • Technology adoption trends and innovation tracking
- • Custom company profiling and benchmarking
Exclusive Sections With Additional Cost
- • Agentic AI Readiness Score
- • TAM, SAM, and SOM Analysis
- • AI Act & Privacy Compliance Audit
- • Channel Partner Ecosystem Mapping
- • China + 1 Strategy Analysis
- • Circular Economy Opportunities Assessment
- • Competitor Benchmarking KPI Analysis
- • Country Trade Analysis
- • Country-level opportunity mapping
- • Digital Maturity Matrix
- • Ecosystem Interdependency Mapping
- • ESG & Decarbonization Roadmap
- • Geopolitical Friction Scorecard
- • Geopolitical Risk Assessment
- • Humanoid Workforce Impact Analysis
- • Investment Heatmap
- • List of Distributors and Channel Partners
- • List of Raw Material Suppliers
- • Market Entry Strategy Assessment
- • Mergers & Acquisitions (M&A) Analysis
- • Patent & Intellectual Property (IP) Analysis
- • Pilot Project Analysis
- • Potential High-Growth Region/Country Investment Assessment
- • Product Comparison Analysis
- • Product Revenue Analysis
- • R&D Investment Analysis in Emerging Technologies
- • Raw Material Scarcity Forecast
Note: For highly customized requirements, deeper strategic assessments, company-specific intelligence, or tailored consulting support, please contact TrendX Insights.
Full Report with Exclusive Insights
Available to clients on request
Explore Our Published Reports Library
This page covers market-level data estimates. For comprehensive published research reports including full methodology, primary data, and detailed company profiles, browse the TrendX Insights Published Reports Library.
Visit Published Reports Library ›11. Related Market Reports
Frequently Asked Questions
The Psoriasis Biologics Market was valued at USD 22.47 Bn in 2025 and is projected to reach USD 46.44 Bn by 2034, growing at a CAGR of 8.4% over the 2026–2034 forecast period.
The Psoriasis Biologics Market is projected to grow at a CAGR of 8.4% from 2026 to 2034.
North America dominated the Psoriasis Biologics Market in 2025, accounting for around 47 percent of global revenue.
The leading companies in the Psoriasis Biologics Market include AbbVie, Johnson and Johnson, Novartis, UCB, Eli Lilly, Bristol Myers Squibb, Leo Pharma, Almirall, Boehringer Ingelheim, Samsung Bioepis.
Il-23 selective inhibitors are achieving market leadership as guselkumab, risankizumab, and tildrakizumab demonstrate superior or comparable skin clearance with more convenient dosing than earlier biologics.
By drug class, the IL-17A inhibitors segment dominated the Psoriasis Biologics Market in 2025, as secukinumab, ixekizumab, and bimekizumab represent the largest psoriasis biologic revenue category driven by superior skin clearance versus TNF inhibitors sustaining dermatologist prescribing preference.
How to Order
Purchasing a TrendX Insights report is straightforward. Our process is designed to be transparent and risk-free for buyers, with a 20% upfront model and full delivery before the balance payment.
This is the price of the syndicated report. Any custom inclusions beyond the Table of Contents will be scoped and priced separately. For the full list of what is covered in the syndicated report, refer to the Table of Contents tab.
A curated, condensed version of this report for students, researchers, and academic institutions. Ideal for thesis work, dissertations, and academic projects. Delivered as PDF to your institutional email.
Valid student ID or institutional email required. For educational and non-commercial use only.